หน้าแรก
ค้นหา
Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer
Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer
Dr. Esteva Discusses Adjuvant Trastuzumab in HER2+ Breast Cancer
Dr. Valdes-Albini on the FDA Approval of Adjuvant Pertuzumab in HER2+ Breast Cancer
Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer
Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer
Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer
Dr. Pegram on Pertuzumab and Trastuzumab in Breast Cancer
Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast Cancer
Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer
Dr. Osborne on Pertuzumab in HER2+ Breast Cancer
Dr. Mittendorf on the Impact of Pertuzumab in HER2+ Breast Cancer
Adjuvant Therapy for High-Risk HER2+ Breast Cancer
Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast Cancer
Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer
Dr. Mark Pegram on Combining Trastuzumab and Pertuzumab
Neratinib + Capecitabine in HER2+ Breast Cancer
Neratinib in HER2+ Breast Cancer
Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer
Dr. Rahman on Pertuzumab and Neratinib in HER2+ Breast Cancer
